ムロモナブ-CD3
ncbi.nlm.nih.gov/pmc/articles/PMC2840233/.
↑ “国立医薬品食品衛生研究所 生物薬品部”. www.nihs.go.jp. 2021年5月7日閲覧。
1 2 3 4 5 “Orthoclone OKT3”. Professional Drug Information. Drugs.com. 2010年1月3日閲覧。
↑ “Therapy with OKT3 monoclonal antibody in refractory T cell acute lymphoblastic leukemia induces interleukin-2 responsiveness”. Leukemia 9 (3): 382–90. (March 1995). PMID 7885036.
1 2 3 Rich, Robert (2013). Clinical immunology : principles and practice (4th ed.). London: Elsevier. ISBN 978-0-7234-3710-9. OCLC 823736017. https://www.sciencedirect.com/book/9780723436911/clinical-immunology
↑ Sgro, C. (1995-12-20). “Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review” (英語).